Accessibility Menu
Guided Therapeutics logo

Guided Therapeutics(OTC) GTHP

Current Price$0.27
Market Cap$26.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1997)-100%
5 Year-58%
1 Year+15%
1 Month+2%
Guided Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.272026-07-22
Guided Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.272026-07-15
1 month+1.89%USD 0.272026-06-22
3 month+35%USD 0.202026-04-22
Year to date-50%USD 0.542025-12-31
1 year+14.89%USD 0.242025-07-22
3 year+98.38%USD 0.142023-07-21
5 year-58.46%USD 0.652021-07-23
Since inception-100%USD 448,717,948.721997-07-01

Guided Therapeutics Financials at a Glance

Market Cap

$26.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$767.00K

Net Income (TTM)

-$3.93M

EPS (TTM)

-$0.05

P/E Ratio

-5.83

Dividend

$0.00

Beta (Volatility)

0.05 (Low)

Price

$0.27

Volume

310

Open

$0.27

Previous Close

$0.27

Daily Range

$0.27 - $0.27

52-Week Range

$0.12 - $0.54

Estimated Earnings Date

May 13, 2026

GTHP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Guided Therapeutics

Guided Therapeutics makes medical devices that help detect cervical cancer early. Its main product, LuViva, scans the cervix without surgery or pain. This device helps doctors find cancer sooner, making treatment easier for patients.

Gadgets That Matter: Products and Services

  • LuViva Advanced Cervical Scan: Non-invasive device for early cervical cancer detection; the majority of revenue in Q2 2025 came from LuViva devices and disposables.
  • Instrumentation Packages: Includes base units, handheld scanners, and mobile carts for clinics and hospitals.
  • Single-Use Cervical Guides: Disposable parts with RFID chips for each patient scan, sold alongside devices.
  • Biophotonics Technology: Uses light to analyze tissue, aiming to expand to other cancers like esophageal cancer.

Plot Twists: Growth and Expansion

  • Signed exclusive manufacturing and distribution deals with SMI (China, in 2019) and Shenghuo Medical (Southeast Asia, in 2016), and partnered with Newmars Medical Technologies (Europe) as a distributor since 2023.
  • Filed for regulatory approval in China (NMPA) in October 2024; U.S. FDA clinical trial ongoing in 2025.
  • Opened a manufacturing site in Hungary in 2025 to reduce tariff risks.
  • Secured new purchase orders from Turkey and Indonesia in 2025, expanding international reach.

Why Guided Therapeutics Stands Out

The company focuses on non-invasive cancer detection using light-based technology. Its global partnerships help reach both developed and developing markets. Manufacturing flexibility and licensing deals support its international strategy.

Five Things You Need to Know

  • Revenue was $117,000 in Q2 2025, up 165.9% from Q2 2023.
  • Gross profit reached $79,000 in Q2 2025, up 618.2% from Q2 2023.
  • Operating expenses were $842,000 in Q2 2025, down from over $2 million in Q2 2023.
  • Net loss was $811,000 in Q2 2025, improving 47.9% from Q2 2023.

Bottom Line

Guided Therapeutics has evolved by focusing on non-invasive cancer detection and expanding through global partnerships. The company faces financial challenges but continues to adapt its business model and reach new markets.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

8

CEO

Mark L. Faupel, PhD

Website

www.guidedinc.com

Headquarters

Peachtree Corners, GA 30092, US

GTHP Financials

Key Financial Metrics (TTM)

Gross Margin

67.93%

Operating Margin

-322.95%

Net Income Margin

-512.65%

Return on Equity

70.53%

Return on Capital

N/A

Return on Assets

-245.14%

Earnings Yield

-17.15%

Dividend Yield

0.00%

Payout Ratio

-2.06%

Stock Overview

Market Cap

$26.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

96.54M

Volume

310

Avg. Volume

11.14K

Financials (TTM)

Gross Profit

$521.00K

Operating Income

-$2.48M

EBITDA

-$2.71M

Operating Cash Flow

-$1.35M

Capital Expenditure

-$2.00K

Free Cash Flow

-$1.36M

Cash & ST Invst.

$369.00K

Total Debt

$2.79M

Guided Therapeutics Performance Analysis

Guided Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 13,000-84.0%
20232023-12-31USD 98,000653.8%
20242024-12-31USD 7,000-92.9%
20252025-12-31USD 767,00010857.1%
Guided Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30-48.7%
Q42025-12-31883.3%
Q12026-03-31-100.0%
Guided Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.15-15.8%
20232023-12-31USD -0.07-52.0%
20242024-12-31USD -0.05-38.5%
20252025-12-31USD -0.04-5.5%
Guided Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-60.3%
Q32025-09-3011.9%
Q42025-12-31-32.3%
Q12026-03-3110.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$24.00K

+4.0%

Gross Margin

0.00%

N/A

Market Cap

$26.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$8.69M

N/A

Employees

3

N/A

Net Income

-$1.01M

-137.2%

EBITDA

-$495.00K

-94.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$369.00K

+220.9%

Total Debt

$2.79M

+38.5%

Accounts Receivable

$4.00K

+100.0%

Inventory

$469.00K

-25.9%

Long Term Debt

$818.00K

+605.2%

Short Term Debt

$1.97M

+2.7%

Return on Assets

-2.45%

N/A

Return on Invested Capital

56.84%

N/A

Free Cash Flow

-$617.00K

-86.4%

Operating Cash Flow

-$617.00K

-86.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CRVWCareView Communications, Inc.
$0.05+0.00%
PYNKFPerimeter Medical Imaging AI, Inc.
$0.23+4.55%
EMITFElbit Imaging Ltd.
$1.60+0.00%
VPTDFVentriPoint Diagnostics Ltd.
$0.08+2.50%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%

Questions About GTHP

What is the current price of Guided Therapeutics?

Guided Therapeutics is trading at $0.27 per share.

What is the 52-week range for Guided Therapeutics?

Over the past 52 weeks, Guided Therapeutics has traded between $0.12 and $0.54.

How much debt does Guided Therapeutics have?

As of the most recent reporting period, Guided Therapeutics reported total debt of $2.79M.

How much cash does Guided Therapeutics have on hand?

Guided Therapeutics reported $369.00K in cash and cash equivalents in its most recent financial results.

What is Guided Therapeutics’s dividend yield?

Guided Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services